Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT with Gefitinib or Temozolomide for NSCLC Brain Metastases
NCT00238251Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2005
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib and temozolomide in non-small cell lung cancer (NSCLC) and brain metastasis (BM), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Overall Survival. Started May 2005; status: completed.
02
Drugs
gefitinibtemozolomide
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT00238251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238251.